InsiderTrades.com logo
Nathan J. Dowden net worth and biography
  • Phone
  • Email
  • Website

Nathan Dowden Biography and Net Worth

President and Chief Operating Officer of Entrada Therapeutics

Nate is President and Chief Operating Officer of Entrada Therapeutics and is responsible for strategic planning, business development, portfolio management, and general operations. Nate joined Entrada as Chief Operating Officer in 2019 with almost 30 years of strategy, investment and operational experience in the healthcare sector. He was promoted to President and Chief Operating Officer in 2024.

Nate was previously Senior Vice President for Corporate Development at Rubius Therapeutics and prior to that he was in Managing Director roles at the Huron Consulting Group and The Frankel Group LLC advising biotechnology, biopharmaceutical, diagnostic and medical device companies. Nate also worked at Ernst & Young advising hospital systems and managed care companies, and at Searle Pharmaceuticals (now part of Pfizer), and CIGNA Healthcare.

Nate holds an MBA from the Booth School of Business at the University of Chicago and a BS from the University of Connecticut.

What is Nathan J. Dowden's net worth?

The estimated net worth of Nathan J. Dowden is at least $2.37 million as of March 10th, 2026. Mr. Dowden owns 198,588 shares of Entrada Therapeutics stock worth more than $2,369,155 as of March 29th. This net worth approximation does not reflect any other investments that Mr. Dowden may own. Learn More about Nathan J. Dowden's net worth.

How do I contact Nathan J. Dowden?

The corporate mailing address for Mr. Dowden and other Entrada Therapeutics executives is , , . Entrada Therapeutics can also be reached via phone at 857-520-9158 and via email at [email protected]. Learn More on Nathan J. Dowden's contact information.

Has Nathan J. Dowden been buying or selling shares of Entrada Therapeutics?

During the last ninety days, Nathan J. Dowden has sold $195,787.02 in shares of Entrada Therapeutics stock. Most recently, Nathan J. Dowden sold 11,894 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $13.05, for a transaction totalling $155,216.70. Following the completion of the sale, the chief operating officer now directly owns 198,588 shares of the company's stock, valued at $2,591,573.40. Learn More on Nathan J. Dowden's trading history.

Who are Entrada Therapeutics' active insiders?

Entrada Therapeutics' insider roster includes John Crowley (Director), Dipal Doshi (CEO), Nathan Dowden (President and Chief Operating Officer), Kush Parmar (Director), Natarajan Sethuraman (Insider), and Kory Wentworth (CFO). Learn More on Entrada Therapeutics' active insiders.

Are insiders buying or selling shares of Entrada Therapeutics?

In the last twelve months, Entrada Therapeutics insiders bought shares 3 times. They purchased a total of 178,044 shares worth more than $1,352,567.90. In the last twelve months, insiders at the sold shares 17 times. They sold a total of 702,385 shares worth more than $5,898,990.58. The most recent insider tranaction occured on March, 10th when COO Nathan J Dowden sold 11,894 shares worth more than $155,216.70. Insiders at Entrada Therapeutics own 8.1% of the company. Learn More about insider trades at Entrada Therapeutics.

Information on this page was last updated on 3/10/2026.

Nathan J. Dowden Insider Trading History at Entrada Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/10/2026Sell11,894$13.05$155,216.70198,588View SEC Filing Icon  
3/9/2026Sell3,116$13.02$40,570.32210,482View SEC Filing Icon  
9/26/2024Sell847$16.00$13,552.00125,149View SEC Filing Icon  
9/9/2024Sell1,904$15.07$28,693.28125,996View SEC Filing Icon  
9/6/2024Sell399$15.19$6,060.81127,900View SEC Filing Icon  
9/6/2023Sell972$13.47$13,092.8448,168View SEC Filing Icon  
7/10/2023Sell3,200$18.00$57,600.0039,273View SEC Filing Icon  
6/22/2023Sell7,097$16.02$113,693.9442,473View SEC Filing Icon  
6/20/2023Sell8,885$14.94$132,741.9049,570View SEC Filing Icon  
10/31/2022Sell2,100$24.05$50,505.0045,283View SEC Filing Icon  
10/24/2022Sell2,404$19.30$46,397.2056,731View SEC Filing Icon  
10/20/2022Sell905$18.07$16,353.3561,906View SEC Filing Icon  
9/26/2022Sell1,544$15.45$23,854.8062,811View SEC Filing Icon  
9/23/2022Sell1,018$15.07$15,341.2664,355View SEC Filing Icon  
9/21/2022Sell3,275$15.13$49,550.7565,373View SEC Filing Icon  
9/15/2022Sell100$15.01$1,501.0068,648View SEC Filing Icon  
9/8/2022Sell912$15.15$13,816.8069,613View SEC Filing Icon  
6/27/2022Sell7,714$13.00$100,282.0064,893View SEC Filing Icon  
See Full Table

Nathan J. Dowden Buying and Selling Activity at Entrada Therapeutics

This chart shows Nathan J Dowden's buying and selling at Entrada Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Entrada Therapeutics Company Overview

Entrada Therapeutics logo
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $11.93
Low: $11.91
High: $12.40

50 Day Range

MA: $11.64
Low: $10.07
High: $13.50

2 Week Range

Now: $11.93
Low: $4.93
High: $13.65

Volume

126,796 shs

Average Volume

235,547 shs

Market Capitalization

$456.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A